See also this year's filing and all EDGAR filings for this company.
PDF Report 0001831363_2023_Terns_Pharmaceuticals_Inc.pdf
Logs
| warning | Expenses in unusual place in relation to revenue | input.sec.calculation_linkbase.edgar_model_mapping | {'expenses_node': 'CostsAndExpenses', 'revenue_node': 'RevenueFromContractWithCustomerExcludingAssessedTax', 'net_inc_node': 'ProfitLoss'} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'100050 - Statement - Statements of Operations and Comprehensive Loss 2': 3, '100060 - Statement - Statements of Operations and Comprehensive Loss': 10}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001831363, Terns Pharmaceuticals Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 285,185,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 757,000 |
| 3 | remainder_Assets | 1,084,000 |
| 4 | LiabilitiesCurrent | 8,468,000 |
| 5 | LiabilitiesNoncurrent | 544,000 |
| 6 | remainder_Liabilities | 1,071,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 22,412,000 |
| 9 | ResearchAndDevelopmentExpense | 39,617,000 |
| 10 | remainder_Expenses | 358,000 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 2,042,000 |
| 13 | remainder_ComprehensiveNetIncome | -484,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 287,026,000 |
| 1 | Liabilities | 10,083,000 |
| 2 | Expenses | 62,387,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 276,943,000 |
| 5 | NetIncome | -60,345,000 |
| 6 | ComprehensiveNetIncome | -60,587,000 |
| 7 | BaseVar | 181,011,000 |
| 8 | EconomicCapitalRatio | 2.80 |
Edgar->Model Mapping
Feature Distribution
Change over Time
